Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
1.
Atheroscler Suppl ; 30: 44-49, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29096860

ABSTRACT

According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. The therapeutic approach for patients with homozygous familial hypercholesterolemia is unambiguous: In addition to LA, in order to improve LDL-C reduction, PCSK9-I could be applied. In patients with heterozygous familial hypercholesterolemia, PCSK9-I is to be applied first. If in addition to a pronounced LDL-C elevation, cardiovascular complications exist or if imaging techniques documented atherosclerotic changes pre-disposing for a cardiovascular event while LDL-C reduction is insufficiently reduced (LDL-C > 100 mg/dl (2.6 mmol/l)), LA treatment should then be applied as last resort. In patients with elevated Lp(a) concentrations (Lp(a) > 60 mg/dl (>120 nmol/l)) and established cardiovascular disease, therapy should rely primarily on LA methods. If in addition to high Lp(a) levels insufficiently treated LDL-C concentrations (LDL-C > 100 mg/dl (2.6 mmol/l)) exist, in rare cases PCSK9-I can supplement the lipid lowering concept.


Subject(s)
Anticholesteremic Agents/therapeutic use , Blood Component Removal/methods , Cardiovascular Diseases/prevention & control , Cholesterol, LDL/blood , Hyperlipoproteinemia Type II/therapy , Lipoprotein(a)/blood , PCSK9 Inhibitors , Serine Proteinase Inhibitors/therapeutic use , Anticholesteremic Agents/adverse effects , Biomarkers/blood , Blood Component Removal/adverse effects , Cardiovascular Diseases/etiology , Combined Modality Therapy , Germany , Humans , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/complications , Hyperlipoproteinemia Type II/enzymology , Proprotein Convertase 9/metabolism , Risk Assessment , Risk Factors , Serine Proteinase Inhibitors/adverse effects , Treatment Outcome
3.
Chirurg ; 83(2): 123-9, 2012 Feb.
Article in German | MEDLINE | ID: mdl-22271054

ABSTRACT

On abdominal CT scans asymptomatic cystic lesions of the pancreas are accidentally detected in 1-2% of patients. Congenital cysts and pancreatic pseudocysts account for two thirds of these lesions. Pancreatic pseudocysts are a frequent complication of acute and chronic pancreatitis. Among resected cystic neoplasms serous cystic adenoma accounts for 30%, mucinous cystic neoplasms for 45% and intraductal papillary mucinous neoplasms for 25%. The diagnosis of a cystic pancreatic lesion is usually made by diagnostic imaging. Symptomatic lesions require definitive therapeutic treatment after appropriate diagnostic work-up. In the diagnosis of asymptomatic cystic lesions several factors are important, among them whether the cyst is connected to the pancreatic duct (as in IPMN and pseudocysts), the size of lesion (for treatment indications) and whether nodules form in the wall of the cyst (a sign of potential malignancy). EUS-guided fine needle aspiration of the cyst fluid adds to the discrimination between benign, premalignant and malignant cystic lesions. Measuring lipase activity, CEA, viscosity and mucin as well as cytology can help in differentiating cystic lesions. An algorithm is discussed for the differential diagnosis and for selection of the appropriate treatment for pancreatic cystic lesions, most of which never require surgery.


Subject(s)
Carcinoma, Pancreatic Ductal/diagnosis , Pancreatic Neoplasms/diagnosis , Algorithms , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/pathology , Carcinoma, Pancreatic Ductal/surgery , Cholangiopancreatography, Magnetic Resonance , Decision Trees , Diagnosis, Differential , Endosonography , Follow-Up Studies , Guideline Adherence , Humans , Image Interpretation, Computer-Assisted , Incidental Findings , Pancreas/pathology , Pancreas/surgery , Pancreatic Cyst/diagnosis , Pancreatic Cyst/mortality , Pancreatic Cyst/pathology , Pancreatic Cyst/surgery , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Pancreatic Pseudocyst/diagnosis , Pancreatic Pseudocyst/mortality , Pancreatic Pseudocyst/pathology , Pancreatic Pseudocyst/surgery , Sensitivity and Specificity , Survival Analysis , Tomography, X-Ray Computed
6.
Pancreatology ; 2(4): 421-4, 2002.
Article in English | MEDLINE | ID: mdl-12138232

ABSTRACT

BACKGROUND/AIMS: Analysis of gene expression is dependent on normalization using housekeeping genes. However, many of these housekeeping genes (e.g. GAPDH, beta-actin) are upregulated in chronic pancreatitis and pancreatic cancer, and cannot be used for normalization. For this reason we tried to identify a housekeeping gene useful for expression analysis in pancreatic diseases. METHODS: RNA isolated from various tissues and states of disease was subjected to reverse transcription and subsequently amplified by PCR using primers for GAPDH and for the ribosomal highly basic 23-kDa (rb 23-kDa, RPL13A) protein. RESULTS: As anticipated, expression of GAPDH varied markedly in the different tissues, whereas the expression of rb 23-kDa was constant in all samples investigated. CONCLUSION: We recommend the use of the ribosomal highly basic 23-kDa protein as a standard for normalization at least for the pancreas and the prostate.


Subject(s)
Gene Expression , Pancreatic Diseases/genetics , Ribosomal Proteins/chemistry , Ribosomal Proteins/genetics , Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Humans , Molecular Weight , RNA, Messenger/metabolism , Reference Standards , Reverse Transcriptase Polymerase Chain Reaction
7.
Clin Cancer Res ; 7(12): 4033-40, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11751498

ABSTRACT

PURPOSE: Mucins are important biomolecules that frequently display an altered expression under pathological conditions. In a search for a unique and reliable marker(s) specific for pancreatic adenocarcinoma, we investigated the expression of different MUC genes in pancreatic tumors and tumor cell lines, in chronic pancreatitis, and in the normal pancreas. EXPERIMENTAL DESIGN: Total RNA from 16 pancreatic tumors, 10 chronic pancreatitis tissues, 7 normal pancreas tissues, and 15 pancreatic tumor cell lines were analyzed by reverse transcription-PCR with primers specific for MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC6, and MUC7 genes and by RNA slot blot analyses. RESULTS: Our results revealed that of all of the mucins examined, only MUC4 displayed a differential expression that was specific for pancreatic adenocarcinoma. Indeed, a substantial number of tumor tissue samples (12 of 16) and tumor cell lines (11 of 15) expressed MUC4 mRNA, whereas samples from chronic pancreatitis (0 of 10) and the normal pancreas (0 of 7) tissues failed to exhibit any detectable level of this mucin. In contrast, no significant alteration was observed in the expression of the other mucins relative to that in the normal pancreas samples. CONCLUSIONS: Overall, this work demonstrates that pancreatic mucin MUC4 is a tumor-associated mucin. Furthermore, the present study introduces a novel avenue to discriminate between pancreatic adenocarcinoma and pancreatitis. Future investigations of the role played by MUC4 in pancreatic adenocarcinoma may prove to be useful in the formulation of strategies for the diagnosis and therapeutic treatment of this malignancy.


Subject(s)
Adenocarcinoma/genetics , Biomarkers, Tumor/analysis , Gene Expression Regulation, Neoplastic , Mucins/genetics , Pancreatic Neoplasms/genetics , Pancreatitis/genetics , Aged , Aged, 80 and over , Chronic Disease , Female , Gene Expression Regulation , Humans , Male , Middle Aged , Mucin-4 , Mucins/analysis , Pancreas/chemistry , RNA/genetics , RNA/isolation & purification , RNA, Neoplasm/genetics , RNA, Neoplasm/isolation & purification , Reference Values , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
8.
Am J Public Health ; 91(11): 1851-6, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11684615

ABSTRACT

OBJECTIVES: This study sought to estimate how changes in state cigarette excise taxes affect the smoking behavior of pregnant women. METHODS: Detailed information about mothers and their pregnancy was used to examine the impact of taxes on the propensity of pregnant women to smoke. The 1989 to 1995 Natality Detail Files were used in conducting analyses to assess the impact of taxes on smoking among different subpopulations. RESULTS: Higher cigarette excise taxes reduced smoking rates among pregnant women. A tax hike of $0.55 per pack would reduce maternal smoking by about 22%. Overall, a 10% increase in price would reduce smoking rates by 7%. Estimates for subpopulations suggested that nearly all would be very responsive to tax changes, including the subpopulations with the highest smoking rates. CONCLUSIONS: Smoking rates among pregnant women are responsive to tax hikes.


Subject(s)
Health Behavior , Maternal Welfare/economics , Smoking/economics , Smoking/epidemiology , Taxes/legislation & jurisprudence , Adolescent , Adult , Female , Humans , Maternal Welfare/statistics & numerical data , Pregnancy , Probability , Public Policy , Smoking Prevention , United States/epidemiology
9.
J Behav Health Serv Res ; 28(3): 319-33, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11497026

ABSTRACT

No recent national data on expenditures and utilization are available to provide a benchmark for reform of mental health systems for children and adolescents. The most recent estimates, from 1986, predate the dramatic growth of managed care. This study provides updated national estimates. Treatment expenditures are estimated to be $11.68 billion ($172 per child). Adolescents have the highest expenditures at $293 per child followed by $163 per child aged 6 to 11 and $35 per preschool-aged child. Outpatient services account for 57%, inpatient for 33%, and psychotropic medications for 9% of the total. Unlike earlier reports, outpatient care now accounts for the majority of expenditures. This finding replicates the differences between recent managed care data and earlier actuarial databases for privately insured adults and confirms the trend from inpatient toward outpatient care.


Subject(s)
Child Health Services/economics , Child Health Services/statistics & numerical data , Health Expenditures/statistics & numerical data , Mental Health Services/economics , Mental Health Services/statistics & numerical data , Adolescent , Ambulatory Care/economics , Ambulatory Care/statistics & numerical data , Child , Child, Preschool , Female , Health Expenditures/trends , Humans , Infant , Insurance, Health/statistics & numerical data , Male , Managed Care Programs/economics , Medicaid/statistics & numerical data , United States , Utilization Review/statistics & numerical data
10.
Obes Res ; 9(8): 486-91, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11500529

ABSTRACT

OBJECTIVE: Recent studies have revealed the presence of a local renin-angiotensin system in adipose tissue. To examine the possible role of this system in adipose tissue, we performed microdialysis studies on the effect of angiotensin II (Ang II) on blood flow and metabolism in abdominal subcutaneous adipose tissue (aSAT) and femoral subcutaneous adipose tissue (fSAT) in young healthy men. RESEARCH METHODS AND PROCEDURES: Using the microdialysis technique, two different protocols were run perfusion with Ringer's solution + 50 mM ethanol with the subsequent addition of 125, 250, and 500 microg/liter Ang II (n = 8) and Ringers's solution + 50 mM ethanol with the subsequent addition of isoproterenol (1 microM) alone and in combination with 500 microg/liter Ang II (n = 6). Dialysate concentrations of ethanol, glycerol, glucose, and lactate were measured for estimating blood flow (ethanol dilution technique), lipolysis, and glycolysis, respectively. RESULTS: Perfusion with Ang II resulted in a dose-dependent decrease in blood flow (fSAT > aSAT), lipolysis (fSAT > aSAT), and glucose uptake (fSAT = aSAT). Isoproterenol increased blood flow and lipolysis at both sites and those effects could be returned to baseline values by the addition of Ang II in aSAT but not fSAT. DISCUSSION: In conclusion, our data indicate that in addition to its well-known vasoconstricting effect, Ang II inhibits lipolysis in adipose tissue, whereby femoral fat depots seem to be more sensitive to this effect than abdominal depots.


Subject(s)
Adipose Tissue/metabolism , Angiotensin II/administration & dosage , Energy Metabolism/drug effects , Lipolysis/drug effects , Renin-Angiotensin System/physiology , Adipose Tissue/anatomy & histology , Adipose Tissue/blood supply , Adult , Dose-Response Relationship, Drug , Humans , Isoproterenol/pharmacology , Male , Microdialysis/methods , Perfusion , Regional Blood Flow/drug effects , Sympathomimetics/pharmacology
11.
Pancreas ; 23(1): 72-9, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11451151

ABSTRACT

BACKGROUND AND AIMS: Programmed cell death via the Fas receptor/Fas Ligand and DR4, DR5/TRAIL plays a major role in tumor escape and elimination mechanisms. It also promises to be an effective therapy alternative for aggressive tumors, as has been recently shown for colon, breast, and lung cancer cells. We attempted to clarify the role of these molecules in aggressivity of pancreatic carcinomas and to identify possible pathways as targets for therapy. METHODS: Five pancreatic cell lines were investigated for the expression of FasL/Fas, DcR3, DR4, DR5/TRAIL, DcR1, DcR2, and other death pathways related molecules such as Bax, bcl-xL, bcl-2, FADD, and caspase-3 by flow cytometry, immunoblotting, and RT/PCR, both semiquantitative and real time (TaqMan). The susceptibility of these cell lines to apoptosis mediated by recombinant TRAIL was investigated. The effect of therapeutic agents (gemcitabine) on their susceptibility to TRAIL induced apoptosis was studied as well. RESULTS: Pancreatic adenocarcinomas expressed high levels of apoptosis-inducing receptors and ligands. They showed differential susceptibility to cell death induced by TRAIL, despite expressing intact receptors and signaling machineries. Treatment with commonly used therapeutic agents did not augment their susceptibility to apoptosis. This could be explained by the fact that they expressed differentially high levels of decoy receptors, as well as molecules known as inhibitors of apoptosis. CONCLUSIONS: The data suggest that pancreatic carcinoma cells have developed different mechanisms to evade the immune system. One is the expression of nonfunctional receptors, decoy receptors, and molecules that block cell death, such as bcl2 and bcl-xL. The second is the expression of apoptosis-inducing ligands, such as TRAIL, that could induce cell death of immune cells. The success in treating malignant tumors by recombinant TRAIL might apply to some but not all pancreatic tumors because of their differential resistance to TRAIL-induced cell death.


Subject(s)
Adenocarcinoma/pathology , Apoptosis/physiology , Arabidopsis Proteins , Deoxycytidine/analogs & derivatives , Membrane Glycoproteins/physiology , Neoplasm Proteins/analysis , Pancreatic Neoplasms/pathology , Tumor Necrosis Factor-alpha/physiology , Adenocarcinoma/chemistry , Antimetabolites, Antineoplastic/pharmacology , Apoptosis/drug effects , Apoptosis Regulatory Proteins , Blotting, Western , Caspase 3 , Caspases/analysis , Computer Systems , Deoxycytidine/pharmacology , Fas Ligand Protein , Fatty Acid Desaturases/analysis , Flow Cytometry , GPI-Linked Proteins , HeLa Cells/chemistry , HeLa Cells/pathology , Humans , Jurkat Cells/chemistry , Jurkat Cells/pathology , Membrane Glycoproteins/analysis , Membrane Glycoproteins/pharmacology , Pancreatic Neoplasms/chemistry , Proto-Oncogene Proteins/analysis , Proto-Oncogene Proteins c-bcl-2/analysis , Receptors, Cell Surface/analysis , Receptors, TNF-Related Apoptosis-Inducing Ligand , Receptors, Tumor Necrosis Factor/analysis , Receptors, Tumor Necrosis Factor, Member 10c , Receptors, Tumor Necrosis Factor, Member 6b , Recombinant Proteins/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , TNF-Related Apoptosis-Inducing Ligand , Tumor Cells, Cultured/chemistry , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/pathology , Tumor Necrosis Factor Decoy Receptors , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/pharmacology , bcl-2-Associated X Protein , bcl-X Protein , fas Receptor/analysis , Gemcitabine
12.
Int J Obes Relat Metab Disord ; 25(4): 581-5, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11319665

ABSTRACT

OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha) is expressed primarily in adipocytes, and elevated levels of this cytokine have been linked to obesity and insulin resistance. Recently, the A allele of a polymorphism in the 5'-flanking region of the TNF-alpha gene (G-308A) has been reported to be more frequent in obese than in lean subjects and has also been associated with increased expression of this cytokine in fat tissue and influences fat mass and insulin resistance. We, therefore, examined the relationship between this variant and obesity in a German Caucasian population. SUBJECTS AND METHODS: We genotyped 176 index subjects recruited within the framework of the BErG (Berlin Ernährung Geschwister)- Study for the TNF-alpha-G-308A polymorphism. Subjects were characterized for weight, height, waist and hip circumference, body mass index (BMI), body composition, glucose tolerance, leptin and angiotensinogen levels. RESULTS: The frequency of the -308A allele (0.18) was similar to that reported previously and genotype distribution was in Hardy-Weinberg equilibrium (GG, n=118; GA, n=53; AA, n=5). There was a significant difference in allele frequencies of the polymorphism by BMI quartiles (I,<27.3 kg/m2; II, 27.3-31.9 kg/m2; III, 31.9-36.5 kg/m2; IV,>36.5 kg/m2, in each quartile n=44) with -308A allele carriers having a higher BMI than G allele carriers (P=0.013). Despite previous smaller studies that have related insulin resistance to the G-308A polymorphism, we found no relationship between glucose and insulin response during an oral glucose tolerance test (OGTT) and the polymorphism. Furthermore, none of the plasma parameters were related to the polymorphism. CONCLUSION: Our findings support the hypothesis that the G-308A polymophism of the TNF-alpha gene is associated with BMI. The G-308A polymorphism may, therefore, represent a genetic marker for increased susceptibility for obesity in Caucasians.


Subject(s)
Obesity/genetics , Polymorphism, Genetic , Tumor Necrosis Factor-alpha/genetics , White People/genetics , Alleles , Body Composition , Female , Gene Frequency , Genetic Markers , Genotype , Glucose Tolerance Test , Humans , Insulin Resistance , Leptin , Male , Middle Aged
14.
Cancer Res ; 61(2): 550-5, 2001 Jan 15.
Article in English | MEDLINE | ID: mdl-11212248

ABSTRACT

Proliferation of fibrotic tissue (desmoplasia) is one of the hallmarks of several epithelial tumors including pancreatic adenocarcinoma. This tissue reaction may be deleterious or advantageous to the host or tumor. In a systematic analysis, we identified two growth factors expressed by human pancreatic carcinoma cells that are positively correlated with the ability to induce fibroblast proliferation both in vitro and in vivo, i.e., transforming growth factor (TGF)-beta1 and fibroblast growth factor-2. Here we demonstrate that the overexpression of TGF-beta1 induced up-regulation of matrix proteins and growth factors in the TGFbeta1-transfected pancreatic tumor cells. Furthermore, transfection of PANC-1 cells induces the same change in fibroblasts in either cocultivation experiments or when they are grown in conditioned medium from TGF-beta1-transfected PANC-1 cells. TGF-beta1-transfected pancreatic tumor cells induced a rich stroma after orthotopical transplantation in the nude mouse pancreas. The transfer of a single growth factor, TGF-beta1, conveys the ability to induce a fibroblast response similar to that seen in desmoplasia in human pancreatic adenocarcinoma. This effect cannot only be attributed to direct effects of TGF-beta1 but also results from the up-regulation of several other factors including collagen type I, connective tissue growth factor, and platelet-derived growth factor.


Subject(s)
Pancreatic Neoplasms/pathology , Transforming Growth Factor beta/metabolism , Animals , Cell Division , Coculture Techniques , Disease Models, Animal , Extracellular Matrix Proteins/metabolism , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/metabolism , Fibroblasts/cytology , Fibroblasts/metabolism , Gene Expression Regulation, Neoplastic , Growth Substances/metabolism , Humans , Immunohistochemistry , Mice , Mice, Nude , Neoplasm Transplantation , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , Transfection , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta1 , Transplantation, Heterologous , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/metabolism , Up-Regulation
15.
Teratog Carcinog Mutagen ; 21(1): 83-96, 2001.
Article in English | MEDLINE | ID: mdl-11135323

ABSTRACT

MUC4 is a membrane-bound mucin and is considered as the human homologue of the rat sialomucin complex (SMC). The deduced structural organization of the wild type-MUC4 cDNA (WT-MUC4) sequence revealed two subunits: a large amino mucin type subunit (MUC4alpha) and a transmembrane subunit (MUC4beta). MUC4beta is a membrane-bound growth factor like subunit and contains three EGF-like domains. The MUC4 gene is expressed in several normal tissues like trachea, lung, and testis. It is not expressed in a normal human pancreas; however, its dysregulation results in high levels of expression in pancreatic tumors and tumor cell lines. Recently, we have demonstrated the presence of alternative splice events in the 3'-end of the MUC4 cDNA that generated new putative variants (sv1-sv10) in normal human testis and in a pancreatic tumor cell line (HPAF). In search of MUC4 variant(s) that are specific to pancreatic adenocarcinoma, we investigated the splicing phenomena in the MUC4 cDNA sequence by using a large panel of pancreatic tumor cell lines. We have identified ten alternative splice events located downstream to the central large tandem repeat domain. These splice events generated 12 variant species (sv4, sv9, sv10-18, and sv21) of MUC4 cDNAs. The deduced amino acid sequence of these variant MUC4 cDNAs revealed two distinct types: a family of secreted and a membrane-associated variant form. Among the members of MUC4 secreted variant family, three (sv4, sv12, and sv13) of ten showed a short 144 residue COOH-terminus compared to 1154 residues in WT-MUC4. The variants with this short COOH-terminus (144 residues) was found in 37% (4/11) of the tumor lines. The putative membrane-bound variant sv10 was detected in 37% (4/11) pancreatic tumor cell lines but not in any normal human tissues. In conclusion, we have identified novel splice variant(s) of MUC4 in pancreatic adenocarcinoma.


Subject(s)
3' Untranslated Regions/genetics , Adenocarcinoma/genetics , Alternative Splicing/genetics , Mucins/genetics , Pancreatic Neoplasms/genetics , Adenocarcinoma/metabolism , Amino Acid Sequence , DNA, Complementary/analysis , DNA, Complementary/classification , DNA, Neoplasm/analysis , Humans , Molecular Sequence Data , Mucin-4 , Mucins/chemistry , Pancreatic Neoplasms/metabolism , Polymorphism, Genetic , RNA, Neoplasm/analysis , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
16.
Teratog Carcinog Mutagen ; 21(1): 97-106, 2001.
Article in English | MEDLINE | ID: mdl-11135324

ABSTRACT

CD44 is an integral cell-surface glycoprotein. Overexpression of the CD44 standard (CD44st) and its variants (CD44v) has been implicated in transformation and progression of many cancer types. Here, we investigated expression of CD44st, CD44v3-7, CD44v7/8, and v10 in five human pancreatic tumor cell lines and normal human pancreatic duct cells transfected with the SV40 large T antigen. CD44st and its variant proteins were quantified using immunocytochemistry and flow cytometry. CD44v7 was expressed at low levels, whereas CD44st, CD44v3, CD44 v4, CD44v, and CD44v6 were expressed at moderate levels in all pancreatic tumor cell lines. In contrast, CD44v7/8 and CD44v10 were expressed at very low levels in two out of the five pancreatic tumor cell lines. Overall, staining of CD44st and CD44 variants was significantly weaker compared to another surface molecule, ICAM-1, reported to be overexpressed in pancreatic cancer cells. Furthermore, the SV40 large T transfected duct cells showed only a weak staining for CD44st, CD44v5, and CD44v6. To determine a possible mechanism for the regulation of surface expression of CD44st, v5 and v6, we incubated Panc-1 cells with bFGF, TGF-beta1, EGF, TNFalpha, and IFNgamma. Only IFNgamma affected the CD44 expression by down-regulation of CD44v6. The constitutive expression of CD44 variants seems to be associated with the malignant state of invasive carcinoma.


Subject(s)
Adenocarcinoma/metabolism , Hyaluronan Receptors/metabolism , Pancreatic Ducts/metabolism , Pancreatic Neoplasms/metabolism , Cell Line, Transformed/drug effects , Cell Line, Transformed/metabolism , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Growth Substances/pharmacology , Humans , Hyaluronan Receptors/classification , Pancreatic Ducts/cytology , Pancreatic Ducts/drug effects , Transfection , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism
17.
Am J Hypertens ; 13(9): 1027-31, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10981554

ABSTRACT

A missense mutation of the beta3-adrenergic receptor gene (ADRB3) resulting in a tryptophan/arginine exchange at position 64 (Trp64Arg polymorphism) has recently been associated with greater capacity to gain weight, a low resting metabolic rate, higher blood pressure, and an early onset of type 2 diabetes. These findings prompted us to examine the relationship between this mutation, blood pressure, and vascular complications in German patients with type 2 diabetes. White patients with type 2 diabetes mellitus (n = 417) were enrolled in the study. The Trp64Arg polymorphism of the ADRB3 gene was detected by polymerase chain amplification and subsequent restriction digest with BstN I. Stepwise logistic regression analysis of the entire study population revealed a significant interaction between gender and genotype (P = .019). We therefore performed separate analyses for men and women. There was a significant relationship between hypertension and the ADRB3 Trp64Arg variant in men (P = .015), but not in women. Furthermore, blood pressure levels in male patients with the minor allele had higher blood pressure levels (P < .05), despite a significantly greater number of antihypertensive medications (P = .01). There was no association between ADRB3 genotype and vascular complications in these patients. In conclusion, our data are compatible with a contribution of this genetic variant of ADRB3 to hypertension in male patients with type 2 diabetes. Further studies will be needed to determine the role of this polymorphism as a predictor of hypertension or vascular complications in patients with type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2/genetics , Diabetic Angiopathies/genetics , Hypertension/genetics , Polymorphism, Genetic/genetics , Receptors, Adrenergic, beta/genetics , Aged , Alleles , Amino Acid Substitution , Blood Pressure , Female , Humans , Hypertension/physiopathology , Male , Middle Aged
18.
Nephrol Dial Transplant ; 15(9): 1384-7, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10978395

ABSTRACT

BACKGROUND: Recent studies have identified a novel polymorphism (C825T) of the gene encoding the beta(3) subunit of heterotrimeric G proteins (G:beta(3)) which is associated with enhanced activation of G-proteins and appears to be more common in hypertensive patients and possibly contributes to decreased kidney allograft survival. METHODS: In the present study we examined the relationship between this genetic variant, type 1 and type 2 diabetes and renal complications of diabetes in 1008 Caucasian patients recruited from an outpatient diabetes clinic and four dialysis centres. We also studied 1940 healthy controls. RESULTS: After multivariate adjustment and in univariate statistics, the G:beta(3) 825TT genotype was not associated with a significantly enhanced risk of diabetes or renal complications. CONCLUSIONS: These findings indicate that the G:beta(3) 825T allele apparently does not contribute to the development of diabetes or associated renal complications in patients with type 1 or type 2 diabetes mellitus.


Subject(s)
Diabetic Nephropathies/genetics , GTP-Binding Proteins/genetics , Adult , Aged , Alleles , Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Female , Gene Frequency , Genetic Predisposition to Disease , Genetic Variation , Genotype , Humans , Male , Middle Aged , Multivariate Analysis , Reference Values
19.
Herz ; 25(1): 15-25, 2000 Feb.
Article in German | MEDLINE | ID: mdl-10713906

ABSTRACT

Essential hypertension is a complex disease influenced by different genetic and environmental factors. The renin-angiotensin system (RAS) is implicated in blood pressure regulation. Angiotensinogen (AGT) is the precursor of the biologically active angiotensin II (Ang II). Initial studies on hypertensive siblings and case-control studies indicated the important role of the angiotensinogen gene (AGT) for the predisposition to essential hypertension, preeclampsia and obesity-related hypertension. Recently, different AGT polymorphisms had been identified and analyzed in case-control studies. The aim of present studies is the analysis of potentially functional AGT variants (C-532T, G-6A), which might be responsible for the regulation of gene expression and therefore AGT generation. The A-6 allele is in complete linkage disequilibrium with the T235 allele and is associated with higher AGT expression in vitro. Segregation linkage analysis demonstrated that the C-532T polymorphism influences plasma AGT variability more significantly than the G-6A variant. Since the C-532T polymorphism is located within a AP-2 consensus element, functional promoter analyses are required. The understanding of the molecular basis of RAS in essential hypertension may provide us with new and more specific pharmacological agents and perhaps the ability to individualize antihypertensive treatment.


Subject(s)
Angiotensinogen/genetics , Hypertension/genetics , Polymorphism, Genetic/genetics , Alleles , Case-Control Studies , Female , Genetic Predisposition to Disease/genetics , Humans , Linkage Disequilibrium/genetics , Obesity/genetics , Pre-Eclampsia/genetics , Pregnancy
20.
J Hypertens ; 17(11): 1563-7, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10608469

ABSTRACT

OBJECTIVE: Aldosterone synthase (CYP11B2) is a key enzyme in the biosynthesis of aldosterone. Recently, the T allele of a polymorphism in the 5'-flanking region of the CYP11B2 gene (C-344T) has been reported to be more frequent in hypertensives than in normotensives, and has also been associated with increased plasma aldosterone levels. We therefore hypothesized that this variant may be related to increased blood-pressure response to dietary salt intake. SUBJECTS AND METHODS: We genotyped 1 63 young normotensive men recruited within the framework of the Berlin Salt-Sensitivity Trial (BeSST) for the CYP11B2 C-344T polymorphism. Subjects were characterized for family history of hypertension, plasma parameters of the renin-angiotensin-aldosterone system and blood-pressure response to a high (220 mmol/day) and low (20 mmol/day) salt diet RESULTS: The frequency of the -344T allele (0.45) was similar to that reported previously and genotype distribution was in Hardy-Weinberg equilibrium (CC, n = 55; CT, n = 71; TT, n = 37). There was a trend towards a higher frequency of the T allele in subjects with a positive family history of hypertension (0.48 versus 0.42), but the C-344T genotype was not related to blood pressure under either diet Furthermore, when subjects were classified into salt-sensitive and salt-resistant groups, allelic distribution did not differ between the two groups (qT = 0.43 versus qT = 0.45). While renin activity and plasma aldosterone levels were not related to genotype, plasma angiotensinogen was significantly higher in T-allele carriers under both the high (P = 0.02) and low (P = 0.008) salt diet. CONCLUSION: Our findings do not support the hypothesis that the C-344T polymorphism of the CYP11B2 gene is associated with salt sensitivity or increased activity of the renin-angiotensin system in young normotensive subjects. It is, therefore, unlikely that the C-344T polymorphism is a genetic marker for salt sensitivity in young normotensive Caucasian men.


Subject(s)
Blood Pressure/drug effects , Cytochrome P-450 CYP11B2/genetics , Hypertension/genetics , Polymorphism, Genetic/genetics , Sodium Chloride/administration & dosage , White People/genetics , Adult , Aldosterone/blood , Alleles , Angiotensinogen/blood , Anthropometry , Cross-Over Studies , Diet, Sodium-Restricted , Drug Resistance , Gene Frequency , Genotype , Humans , Male , Polymorphism, Genetic/physiology , Renin/blood , Single-Blind Method , Sodium Chloride/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...